文献速递白血病

吉西他滨联合顺铂±维利帕尼治疗gBRCA/PALB2突变胰腺癌的随机II期试验

Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
PubMed 文献 · J Clin Oncol · 2020-01-24

该随机多中心II期试验评估吉西他滨联合顺铂(A组)对比联合维利帕尼(B组)在携带gBRCA/PALB2突变的晚期胰腺导管腺癌患者中的疗效。结果显示两组客观缓解率分别为74.1%和65.2%,差异无统计学意义;结论认为顺铂联合吉西他滨是有效方案,加用维利帕尼未提高缓解率。

要点

  • 顺铂联合吉西他滨在gBRCA/PALB2+晚期胰腺癌中客观缓解率达74.1%。
  • 加用维利帕尼未显著改善缓解率或生存终点。
  • 含维利帕尼组3-4级血液学毒性(血小板减少55% vs 9%)更高。

核心结论

  • 顺铂联合吉西他滨是晚期gBRCA/PALB2+胰腺导管腺癌的有效方案。
  • 同步加用维利帕尼未提高缓解率。

研究设计与样本

  • 开放标签、随机、多中心、两臂II期试验。
  • 纳入未经治疗、可测量III-IV期、ECOG体能状态0-1的gBRCA/PALB2+胰腺导管腺癌患者。

主要发现

  • A组中位总生存15.5个月(95%CI 12.2-24.3),B组16.4个月(95%CI 11.7-23.4)(P=0.6)。
  • 全队列2年总生存率30.6%(95%CI 17.8%-44.4%),3年总生存率17.8%(95%CI 8.1%-30.7%)。

关键数值与推荐

  • A组3-4级中性粒细胞减少13例(48%),B组7例(30%)。
  • A组3-4级血小板减少15例(55%),B组2例(9%)。
  • A组3-4级贫血14例(52%),B组8例(35%)。

临床怎么用

  • 对于gBRCA/PALB2+晚期胰腺癌,可考虑顺铂联合吉西他滨作为标准方案。
  • 不推荐在顺铂联合吉西他滨基础上常规加用维利帕尼。

局限性

  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Five percent to 9% of pancreatic ductal adenocarcinomas (PDACs) develop in patients with a germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutation. Phase IB data from a trial that used cisplatin, gemcitabine, and veliparib treatment demonstrated a high response rate (RR), disease control rate (DCR), and overall survival (OS) in this population. We designed an open-label, randomized, multicenter, two-arm phase II trial to investigate cisplatin and gemcitabine with or without veliparib in gBRCA/PALB2+ PDAC. PATIENTS AND METHODS: Eligible patients had untreated gBRCA/PALB2+ PDAC with measurable stage III to IV disease and Eastern Cooperative Oncology Group performance status of 0 to 1. Treatment for patients in arm A consisted of cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 intravenously on days 3 and 10; treatment for patients in arm B was the same as that for patients in arm A, and arm A also received veliparib 80 mg orally twice per day on days 1 to 12 cycled every 3 weeks. The primary end point was RRs of arm A and arm B evaluated separately using a Simon two-stage design. Secondary end points were progression-free survival, DCR, OS, safety, and correlative analyses. RESULTS: Fifty patients were evaluated by modified intention-to-treat analysis. The RR for arm A was 74.1% and 65.2% for arm B (P = .55); both arms exceeded the prespecified activity threshold. DCR was 100% for arm A and 78.3% for arm B (P = .02). Median progression-free survival was 10.1 months for arm A (95% CI, 6.7 to 11.5 months) and 9.7 months for arm B (95% CI, 4.2 to 13.6 months; P = .73). Median OS for arm A was 15.5 months (95% CI, 12.2 to 24.3 months) and 16.4 months for arm B (95% CI, 11.7 to 23.4 months; P = .6). Two-year OS rate for the entire cohort was 30.6% (95% CI, 17.8% to 44.4%), and 3-year OS rate was 17.8% (95% CI, 8.1% to 30.7%). Grade 3 to 4 hematologic toxicities for arm A versus arm B were 13 (48%) versus seven (30%) for neutropenia, 15 (55%) versus two (9%) for thrombocytopenia, and 14 (52%) versus eight (35%) for anemia. CONCLUSION: Cisplatin and gemcitabine is an effective regimen in advanced gBRCA/PALB2+ PDAC. Concurrent veliparib did not improve RR. These data establish cisplatin and gemcitabine as a standard approach in gBRCA/PALB2+ PDAC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Reilly EM, Lee JW, Zalupski M, et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020. PMID: 31976786. doi:10.1200/JCO.19.02931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。